Dyne Therapeutics, Inc.(DYN)Earnings, Financials & Key RatiosDyne Therapeutics, Inc. (DYN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the $753.1 million cash position provides a solid runway, the persistent quarterly free cash flow burn of $145.1 million warrants caution until clinical milestones are achieved.
Dyne Therapeutics, Inc. (DYN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Dyne Therapeutics, Inc. (DYN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.73vs $0.77+5.5% | — |
| Q2 2026 | Mar 2, 2026 | $0.76vs $0.74-2.7% | — |
| Q4 2025 | Nov 5, 2025 | $0.76vs $0.81+6.2% | — |
| Q3 2025 | Jul 28, 2025 | $0.97vs $0.99+2.0% | — |
Recent stock market news and headlines for Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven neuromuscular diseases. Recursion Pharmaceuticals utilizes an artificial intelligence OS to accelerate drug discovery across several therapeutic areas.
Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform. Vertex Pharmaceuticals maintains a dominant market share in cystic fibrosis while expanding its reach into gene editing and pain management.
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings more than three decades of biopharmaceutical industry experience and a track record of building and scaling innovative companies from development through commercialization across rare diseases, neuroscience, and oncology.
Key metrics vs top competitors for Dyne Therapeutics, Inc. (DYN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $23.83 | $3.94B | -6.87 | — | — | -55.71% | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $60.35 | $11.61B | 33.53 | 12.87% | 8.29% | 4.41% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — |
Dyne Therapeutics, Inc. (DYN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Dyne Therapeutics, Inc. (DYN) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 11, 2026·SEC
Mar 2, 2026·SEC
Jan 12, 2026·SEC
Get notified when DYN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Dyne Therapeutics, Inc. (DYN) stock FAQ — growth, dividends, profitability & financials explained
Dyne Therapeutics, Inc. (DYN) reported a net loss of $451.7M for fiscal year 2025.
Dyne Therapeutics, Inc. (DYN) has a return on equity (ROE) of -55.7%. Negative ROE indicates the company is unprofitable.
Dyne Therapeutics, Inc. (DYN) had negative free cash flow of $462.2M in fiscal year 2025, likely due to heavy capital investments.
